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http://www.darujps.com/content/20/1/15RESEARCH ARTICLE Open AccessFabrication of docetaxel surfaced Fe3O4
magnetite nanoparticles and their cytotoxicity on
4 T1 breast cancer cells
MH Yazdi1, Z Niazzadeh Najafi1, MR Khorramizadeh2, M Amini3 and AR Shahverdi1*Abstract
Background: In the recent years, there is an increasing attention to the using of Fe3O4 magnetite nanoparticles
(MNPs) as drug delivery systems. Application of this nanoparticles could profit advantages of nanomedicine to
enhance biological activity of pharmaceutical ingredients.
Methods: Fe3O4 MNPs were synthesised by a chemical method and characterized by transmission electron
microscopy and energy-dispersive spectroscopy techniques. In the next step, docetaxel-coated Fe3O4 MNPs were
prepared, using percipitation method. The surface chemistry of docetaxel-coated Fe3O4 MNPs as well as their
thermal decomposition characteristics were examined using fourier transform infrared spectroscopy and
thermogravimetric analyzer equipment, respectively. The cytotoxicity assay was conducted on 4 T1 breast cancer
carsinoma by MTT assay to evaluate the possible in vitro antiproliferative effects of docetaxel-coated Fe3O4 MNPs.
Results: During precipitation process, docetaxel molecules were precipitated on the surface of Fe3O4 MNPs by the
ratio of 3:100 w/w which indicates that each milligram of coated Fe3O4 MNPs averagely contained 30 μg pure
docetaxel compound. Docetaxel showed aniproliferative effects against mentioned cell line. The higestest
concentartion of docetaxel (80 μg/ml) caused about 80% cell death. However, the results demostarted that much
lower amounts of docetaxel will be needed in combination of Fe3O4 MNPs to produce the potent antiproliferative
effect compared to docetaxel alone. Dose response cytotoxicity assay of docetaxel-coated Fe3O4 MNPs against 4 T1
breast cancer cells showed that lower amount of docetaxel (0.6 μg/ml) can exhibit higher cytotoxic effect against
this cancer cell line (90% cell death).
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Today, side effects of anti cancer drugs are still considered
as a major problem in chemotherapy of cancer diseases (1).
In the recent years, new drug delivery systems have been
developed to reduce the side effects of these drugs (2–4).
These systems mainly include nanotubes (5), liposomes (6),
dendrimers (7) and nanoparticles (8). The potential bio-
medical applications of Fe3O4 magnetite nanoparticles
(MNPs) are well discussed in the literature (9). Due to their
magnetic properties, these nanomaretials have recieved
particular attention as possible drug carriers (10). The* Correspondence: shahverd@sina.tums.ac.ir
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reproduction in any medium, provided the orconjugation of chemical or natural anticancer drugs to
Fe3O4 magnetite nanoparticles (MNPs) can lead to increse
the uptake of anticancer agents by targeted tumor and im-
prove their therapeutic index (11). For example, a signifi-
cant difference in antiproliferation effect of a natural
product, umbelliprenin, and its Fe3O4 MNPs-conjugated
form was observed in vitro model (12).
Docetaxel (Figure 1) is an insoluble semi-synthetic
analogue of Taxol. Docetaxel leads to a significant decrease
in free tubulin, required for microtubule formation, and
results in inhibition of mitotic cell division between meta-
phase and anaphase, preventing further cancer cell progeny
(13). In this study, docetaxel-coated Fe3O4 MNPs have
been fabricated to determine the antiproliferative effect of
this anticancer agent in combination with Fe3O4 MNPs
against 4 T1 breast cancer cell line. The main hypothesis istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The structure of docetaxel.
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ation of Fe3O4 MNPs on 4 T1 breast cancer cells com-
pared to the cytotoxicity of docetaxel alone.
Materials and methods
Synthesis of Fe3O4 magnetic nanoparticles and their
characterization
A previously reported method was used for synthesis of
Fe3O4 MNPs (14). Briefly, deionized water (200 ml) was
deoxygenated by bubbling nitrogen gas for 1.5 h, then
50 ml of NH4OH (1 M) was added and the mixture was
stirred with mechanical agitation at 1000 rpm. Then,
amounts of 6.76 g FeCl3.6H2O (2.5 mmol) and 4.97 g
FeCl2.4H2O (2.5 mmol) were separately dissolved in
50 ml distilled water to make 0.5 M solutions. Subse-
quently, amounts of 10 ml ferrous chloride and 20 ml
ferric chloride solutions were added to the ammonium
hydroxide solution and the reaction mixture was stirred
for 2.5 min at 1000 rpm. At this stage, a black precipi-
tate formed which was washed four times with deionized
water. Finally, using a magnet, the prepared Fe3O4
MNPs were separated from the solution. Freshly pre-
pared Fe3O4 MNPs were characterized by transmission
electron microscopy (model EM 208 Philips) and
energy-dispersive spectroscopy (EDS).
Preparation of docetaxel-coated Fe3O4 nanoparticles and
their surface characterization
In order to coat docetaxel on the surface of Fe3O4
MNPs, a simple precipitation method (Figure 2) was
used as follows: A 2 mg/ml dichloromethane solution of
docetaxel (Cipla, Mumbai, India) was prepared and
reserved in a sealed container. Fe3O4 MNPs (100 mg)
were dispersed in 5 ml distilled water. Thereafter,
amount of 5 ml dichloromethane solution of docetaxel
was added drop-by-drop to the suspension of Fe3O4
MNPs over a 15 min period under continuously stirring
(300 rpm) condition, and using a laboratory magnetic
stirrer. The resulting mixture was maintained in a static
regime at 45°C for 24 hours. Docetaxel-coated Fe3O4MNPs was separated from the solution by a magnet. Fi-
nally, the capped nanoparticles were washed three times
with distilled water. A stock suspension of Fe3O4 MNPs
and docetaxel-coated Fe3O4 MNPs were prepared
(2 mg/ml) and used for antiproliferative bioassay. The
surface chemistry of the docetaxel-coated Fe3O4 MNPs
was studied using Fourier transform infrared spectros-
copy (Nicolet Magna 550). Also thermal decomposition
characteristics of docetaxel-coated Fe3O4 MNPs were
determined using Thermogravimetric Analyzer TGA
equipment as well.
Cell culture
The 4 T1 breast cancer cell line was obtained from the
National Cell Bank of Iran (NCBI), Pasteur Institute of
Iran, Tehran (Iran). The cells were cultured in a RPMI-
1640 medium with 10% fetal calf serum, 100 u/ml peni-
cillin and 100 μg/ml of streptomycin in 5% CO2 at 37°C
for one week and then used for cell proliferation assay.
Cell proliferation assay
Thiazolyl blue tetrazolium bromide assay (MTT) was
performed to evaluate cell proliferation where 2 × 104
cells were seeded in 96 well plates and incubated with 0,
10, 20, 40 and 80 μg/ml of docetaxel-Fe3O4 MNPs,
bared Fe3O4 MNPs or docetaxel alone for 24 hours.
Then, 15 μl MTT (0.5 mg/ml) was added to each well,
and the plates were incubated for 2 hrs. Then, the
medium was replaced with 200 μl of DMSO and the ab-
sorbance was recorded at 570 nm (12). Each experiment
was repeated three times and MTT assay was performed
in 3 replicates for each experiments. The percentage of
inhibition rate (IR) was measured using the following
equation:
IR %ð Þ ¼ 1  ODexp=ODcon½   100
Where ODexp and ODcon were optical densities of
treated and untreated cells, respectively. Finally, The
percentage-inhibition curve was obtained by plotting
“the percentage of inhibition” (i.e.[absorbance of test
wells/absorbance of control wells]/100) against the con-
centration of cytotoxic compounds, compared to control
(i.e. untreated) cells.
Results
Preparation and characterization of Fe3O4 MNPs
As mentioned earlier, Fe3O4 MNPs were chemically
synthesized and their shape as well as size properties
were confirmed by transmission electron microscopy.
Upper illustration in Figure 3 demonstrates a representa-
tive TEM image of synthesized Fe3O4 MNPs. TEM
image shows that the particles range in size below than
20 nm and possess an average size of 10 nm. The lower
Figure 2 Schematic presentation of the simple fabrication of docetaxel coated Fe3O4 MNPs used during study.
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spectrum of Fe3O4 MNPs revealed the presence of Fe
and O elements peaks. These EDS peaks confirm the ex-
istence of iron-oxide nanoparticles. It should beFigure 3 TEM image of chemically-synthesized Fe3O4 MNPs
(upper illustration) indicate that that Fe3O4 MNPs are well
below 20 nm in size. The magnetic forces between iron oxide
particles -fortified by high surface area of nanoparticles- caused
agglomeration among MNPs. Lower illustration shows energy
dispersive spectrum (EDS) of Fe3O4 MNPs which confirms the
presence of Fe and O atoms and the existence of iron-oxide
nanoparticles. Additional peaks, of copper and carbon elements are
attributed to the grid used for TEM imaging.mentioned that additional peaks, belonging to copper
and carbon element are attributed to the grid used for
TEM imaging.Preparation and surface characterization of docetaxel
coated Fe3O4 MNPs
After drop-by-drop addition of the organic solution of
docetaxel to Fe3O4 MNPs slurry, docetaxel molecules
precipitated on the surface of the Fe3O4 nanoparticles by
the ratio of about 3/100 w/w (it means that 1000 μg of
coated Fe3O4 MNPs nanoparticles contained almost
30 μg docetaxel). This ratio was simply determined grav-
imetrically by weighing the coated Fe3O4 MNPs before
and after it was washed with chloroform as solvent, for
three times as well as the results obtained from thermo-
gravimetric assay. Figure 4 demonstrates weight loss of
docetaxel-coated Fe3O4 MNPs as a function of
temperature which was determined using this method.
This weight loss (%3) in the TGA curve indicated carbon
oxidation which proved the presence of organic moietiesFigure 4 Weight loss of docetaxel-coated Fe3O4 MNPs as a
function of temperature which was determined using
thermogravimetric method. This weight loss in the TGA curve
indicated carbon oxidation which proved the presence of organic
moieties in the sample, thereby confirming that Fe3O4 MNPs are
truly coated with docetaxel molecules.
Table 1 The FTIR spectroscopy data of Fe3O4 MNPs,
docetaxel and docetaxel coated Fe3O4 MNPs




2922, 2927, 1736, 1246, 1161, 1065
docetaxel alone 3487, 3377, 2937, 1735, 1712, 1246, 1169, 1072
Underlined data shows common corresponding peaks in FTIR spectra of
docetaxel-coated Fe3O4 MNPs and docetaxel.
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truly coated with docetaxel molecules. The associated
FTIR spectroscopic data of docetaxel-coated Fe3O4
MNPs, docetaxel-free Fe3O4 MNPs and docetaxel alone,
are outlined in Table 1; which further confirmed the
presence of docetaxel on the surface of synthesized
Fe3O4 MNPs. In terms of chemical bonding, a main
interaction is expected to occur between Fe3O4 MNPs
and docetaxel: electrostatic bounds may form between
carbonyl oxygen and hydroxyl groups of docetaxel with
Fe chelating agent in Fe3O4 crystal (Table 1). This inter-
action lead to disappear of hydroxyl bands centered at
3487 and 3377 cm-1 in FTIR spectrum of docetaxel-






















Docetaxel coated Fe3O4 NPs
Fe3O4 NPs
Figure 5 Antiproliferative effect of Fe3O4 MNPs, docetaxel and
docetaxel-coated Fe3O4 MNPs against 4 T1 breast cancer.make docetaxel -coated Fe3O4 MNPs a suitable carrier
with bipolar properties which penetrates into both
hydrophilic and hydrophobic (i.e. cell membrane) fluids
at the same time.
Antiproliferative effects
Antiproliferative effects of docetaxel-coated Fe3O4 MNPs,
docetaxel alone, and Fe3O4 MNPs alone were in vitro eval-
uated at different concentrations on 4 T1 breast cancer
cells. Cytotoxicity analysis of samples suggested a direct
dose–response relationship, in which cell proliferation
decreased in higher concentrations (Figure 5). Samples
were found to have different cytotoxicities on 4 T1 breast
cancer cells, with docetaxel-coated nanoparticles being the
most potent. The antiproliferative effect of test compounds
increased in the following order: docetaxel < Fe3O4
MNPs<docetaxel-coated Fe3O4 MNPs. Moreover, the ne-
cessary concentrations to cause 50% cell death (IC50) were
more than 30 and 40 (μg/ml) in cells treated with Fe3O4
MNPs alone and docetaxel, respectively. Docetaxel-coated
Fe3O4 MNPs could cause the same effect at 10 μg/ml con-
centration. In other words, the combination of docetaxel
and Fe3O4 MNPs exhibited a much more potent antiproli-
ferative activity than docetaxel and Fe3O4 MNPs alone. As
clear in Figure 5, docetaxel at concentrations of 20 and 30
(μg/ml), moderately reduced the proportion of viable cells
to 70% and 50%, respectively. The cytotoxicity curve for
Fe3O4 MNPs alone followed almost similar pattern, though
sharper. The percentage of viable cell number sharply
decreased from 87% at the concentration of 10 μg/ml to
35% at 40 μg/ml concentration. In contrast, however, only
the low concentration of 10 μg/ml docetaxel-coated Fe3O4
MNPs (equivalent to the concentration of approximately
0.3 μg/ml pure docetaxel), drastically reduced the propor-
tion of viable cells by more than 70%. Also a considerable
cytotoxicity (about 90%) was observed for 20 μg/ml
docetaxel-coated Fe3O4 MNPs against 4 T1 breast cancer
cells. In higher concentrations (>20 μg/ml), this proportion
declined steadily, until it reached the remarkably-low
amount of about 7% at 80 μg/ml concentration.
Discussion
Literature review shows that there are numerous reports
on cytotoxicity of docetaxel in combination of different
carrier (15,16). However, the efficiency of this compound
in conjugation with Fe3O4 MNPs has not been yet investi-
gated. Here, the antiproliferative effect of docetaxel
enhanced in tumor cells when it was coated on the surface
of Fe3O4 MNPs has been reported. As mentioned earlier,
Fe3O4 MNPs, docetaxel and docetaxel-coated Fe3O4
MNPs, all showed antiproliferative effects on 4 T1 breast
cancer cells, increasing in the order: docetaxel < Fe3O4
MNPs< docetaxel-coated Fe3O4 MNPs. It is noticeable
that based on current study, docetaxel has considerable
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centrations of not below 10 μg/ml. However, obtained
results demonstrated that when coated on Fe3O4 MNPs
surface, docetaxel have antiproliferative effect, even at the
low concentration of 0.3 μg/ml. This literally means that
much lower amounts of docetaxel will be needed to pro-
duce the same antiproliferative effect as docetaxel alone.
As described in above, during precipitation process, doce-
taxel molecules were precipitated on the surface of Fe3O4
MNPs by the ratio of 3/100 w/w which indicates that each
milligram of coated Fe3O4 MNPs averagely contained
30 μg pure docetaxel compound. Therefore, it is deducible
from Figure 5, that the concentration of 80 μg/ml doce-
taxel caused 79% cell death. However, when combined
with Fe3O4 MNPs, the average concentration of 0.6 μg/ml
docetaxel (which is equivalent to the concentration of
about 20 μg/ml docetaxel- Fe3O4 MNPs) caused more
than 90% cell death. Thus, it is concluded that by coating
docetaxel on the surface of Fe3O4 MNPs, the required
amount of docetaxel for showing a potent antiproliferative
effects against 4 T1 breast cancer cells could be consider-
ably lowered (more than 100 fold). As mentioned before,
many pharmaceutical compounds have low solubility in
biological fluids, which reduces their efficiency in in vivo
models. Therefore, it is hypothesized that, Fe3O4 MNPs
may be considered as efficient carriers for these insoluble
compounds.Conclusion
In this paper, the antiproliferative effect of docetaxel
(IC50 =40 μg/ml) has been reported and the results
revealed that the combination of Fe3O4 MNPs and doce-
taxel is significantly more cytotoxic (IC50 =10 μg/ml)
than docetaxel alone. In conclusion, this result is of par-
ticular value since it demonstrates that by using metallic
nanoparticles in combination therapy, lower amounts of
these materials might be required, resulting in reduction
of the potential hazards of docetaxel usage. Further inves-
tigations are needed to determine the antiproliferative ef-
fect of docetaxel-coated Fe3O4 MNPs in other cell lines.
Moreover, studies on cytotoxic effects of docetaxel-coated
Fe3O4 MNPs in animal models will be of great value.
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